Zobrazeno 1 - 10
of 131
pro vyhledávání: '"Michael S. Kinch"'
Publikováno v:
Journal of Clinical and Translational Science, Vol 6 (2022)
The last 50 years have seen an increasing dependence on academic institutions to develop and commercialize new biomedical innovations, a responsibility for which many universities are ill-equipped. To address this need, we created LEAP, an asset deve
Externí odkaz:
https://doaj.org/article/6fab0e6a7b83418da44ce588bfb03310
Publikováno v:
Expert Review of Vaccines, Vol 16, Iss 12, Pp 1253-1266 (2017)
Introduction: A survey of FDA-approved biologicals focused upon the development of immunotherapies over time to gain insight on the challenges and trends of vaccine development today. Areas covered: A total of 135 different immune-based therapies wer
Externí odkaz:
https://doaj.org/article/9269ef3958e24615b74d91a1d274149f
Publikováno v:
Journal of Clinical and Translational Science, Vol 5, Pp 43-43 (2021)
ABSTRACT IMPACT: This work aims to identify best practices for university-based asset development programs to improve commercialization throughput, which in turn will drive innovation in the biomedical space and directly contribute to improved human
Externí odkaz:
https://doaj.org/article/6bd04e86727e40c0b3f2ec2531a46e0b
Autor:
Charles N. Landen, Tae-Jin Kim, Yvonne G. Lin, William M. Merritt, Aparna A. Kamat, Liz Y. Han, Whitney A. Spannuth, Alpa M. Nick, Nicholas B. Jennnings, Michael S. Kinch, David Tice, Anil K. Sood
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 10, Iss 11, Pp 1259-1267 (2008)
The αvβ3 integrin is expressed on proliferating endothelial cells and some cancer cells, but its expression on ovarian cancer cells and its potential as a therapeutic target are unknown. In this study, expression of the αvβ3 integrin on ovarian c
Externí odkaz:
https://doaj.org/article/f1b1524dd8434c41b2694de3d3bf3073
Publikováno v:
Drug Discovery Today. 27:2057-2064
The year 2021 witnessed a remarkable number of US Food and Drug Administration (FDA) approvals and registered clinical trials. In total, 60 new molecular entities (NMEs) were approved by the FDA, the highest level achieved in the post-Prescription Dr
Autor:
Peter A. Kiener, Peter Kufer, Patrick A. Baeuerle, Steve Coats, Michael S. Kinch, Elizabeth Bruckheimer, Bernd Schlereth, Petra Lutterbuese, Shannon Roff, Ralf Lutterbuese, Scott A. Hammond
Supplementary Video 4E and F from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87ff43afd7719579e8bf5feb86d176bf
https://doi.org/10.1158/0008-5472.22368474.v1
https://doi.org/10.1158/0008-5472.22368474.v1
Autor:
Peter A. Kiener, Peter Kufer, Patrick A. Baeuerle, Steve Coats, Michael S. Kinch, Elizabeth Bruckheimer, Bernd Schlereth, Petra Lutterbuese, Shannon Roff, Ralf Lutterbuese, Scott A. Hammond
Supplementary Video 4I from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52902e6df683fe3dd79dcd5f71090458
https://doi.org/10.1158/0008-5472.22368459
https://doi.org/10.1158/0008-5472.22368459
Autor:
Peter A. Kiener, Peter Kufer, Patrick A. Baeuerle, Steve Coats, Michael S. Kinch, Elizabeth Bruckheimer, Bernd Schlereth, Petra Lutterbuese, Shannon Roff, Ralf Lutterbuese, Scott A. Hammond
The EphA2 receptor tyrosine kinase is frequently overexpressed and functionally altered in malignant cells and thus provides opportunities for selective targeting of tumor cells. We describe here the development of a novel, bispecific single-chain an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c189f7613093524823cf07cbcace9bc
https://doi.org/10.1158/0008-5472.c.6495966
https://doi.org/10.1158/0008-5472.c.6495966
Autor:
Peter A. Kiener, Peter Kufer, Patrick A. Baeuerle, Steve Coats, Michael S. Kinch, Elizabeth Bruckheimer, Bernd Schlereth, Petra Lutterbuese, Shannon Roff, Ralf Lutterbuese, Scott A. Hammond
Supplementary Video 4A and B from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cb96db4aacf3d3bf4abfc764fa4edac
https://doi.org/10.1158/0008-5472.22368495
https://doi.org/10.1158/0008-5472.22368495
Autor:
Peter A. Kiener, Peter Kufer, Patrick A. Baeuerle, Steve Coats, Michael S. Kinch, Elizabeth Bruckheimer, Bernd Schlereth, Petra Lutterbuese, Shannon Roff, Ralf Lutterbuese, Scott A. Hammond
Supplementary Video 4G and H from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::243a483eab733bc03468e9813b5dab59
https://doi.org/10.1158/0008-5472.22368468
https://doi.org/10.1158/0008-5472.22368468